Posted: Tuesday, August 11, 2020
Prashant Kapoor, MD, and Shaji Kumar, MD, both of the Mayo Clinic, discuss data from the STaMINA study, which suggest a progression-free survival benefit with tandem autologous hematopoietic cell transplantation in patients with high-risk multiple myeloma.